Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.

In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC...

Full description

Bibliographic Details
Main Authors: Jesper Waldenström, Johan Westin, Kristina Nyström, Peer Christensen, Olav Dalgard, Martti Färkkilä, Karin Lindahl, Staffan Nilsson, Gunnar Norkrans, Henrik Krarup, Hans Norrgren, Mads Rauning Buhl, Stephan Stenmark, Martin Lagging
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4864304?pdf=render

Internet

http://europepmc.org/articles/PMC4864304?pdf=render

Similar Items